Eagleye Technology (02251) spent approximately HKD 41,500 to repurchase 4,000 shares on July 16th.
Eagle Eye Technology (02251) announced that on July 16, 2026, the company repurchased 4,000 shares at a cost of approximately 41,500 Hong Kong dollars, with a repurchase price of 10.29 to 10.52 Hong Kong dollars per share.
Eagle Eye Technology (02251) announced that on July 16, 2026, the company repurchased approximately HK$41,500 worth of 4,000 shares at a repurchase price of HK$10.29 to HK$10.52 per share.
Related Articles
CSPC PHARMA (01093): The Phase III clinical trial of SYS 6043 for the treatment of platinum-resistant advanced ovarian cancer, primary peritoneal cancer, and fallopian tube cancer has officially started at the first center in China.
Inner Mongolia Xingye Silver & Tin Mining (000426.SZ) subsidiary plans to subscribe for 20% of the shares of the Australian listed company TAT.
Step out of the shadow of historic collapse! UnitedHealth Group Incorporated (UNH.US) significantly raises full-year guidance, blowing the horn of recovery with better-than-expected financial report.
CSPC PHARMA (01093): The Phase III clinical trial of SYS 6043 for the treatment of platinum-resistant advanced ovarian cancer, primary peritoneal cancer, and fallopian tube cancer has officially started at the first center in China.
Inner Mongolia Xingye Silver & Tin Mining (000426.SZ) subsidiary plans to subscribe for 20% of the shares of the Australian listed company TAT.
Step out of the shadow of historic collapse! UnitedHealth Group Incorporated (UNH.US) significantly raises full-year guidance, blowing the horn of recovery with better-than-expected financial report.
RECOMMEND
